Mr. Whalen has more than 20 years of experience in the healthcare industry leading and supporting transactions involving acquisitions, co-promotions, out licenses and strategic alliances.  Mr. Whalen joined Horizon Pharma in April of 2010 and has led or supported Horizon’s acquisitions since that time helping to grow Horizon from a pre-commercial company with no sales to over $750 million in net sales in 2015.  Recent transactions include Horizon’s acquisitions of Crealta Holdings LLC for $510 million and PENNSAID® 2% for $45 million.  He also led the out licensing of LODOTRA® and DUEXIS® ex-U.S. and has supported Horizon’s IPO and other fund raising activities.  

Prior to Horizon, he was at Baxter Healthcare where he led and supported a number of transactions as part of Baxter’s Medication Delivery business.  Mr. Whalen worked at Searle prior to Baxter where his experience included various finance roles supporting business development, European operations, U.S. marketing, and R&D.  

He earned a MBA from the University of Illinois and bachelor’s degree from the University of Notre Dame.